FDA Approves FOSAPREPITANT — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals received FDA approval on Friday for the generic version of the antiemetic Fosaprepitant dimeglumine (ANDA209965), signaling further intensification of price competition known to slash drug costs for hospitals. This FDA action is expected to bolster Novadoz’s pipeline and accelerate market share gains in the generic anti-nausea injectable market, which faces significant pricing pressure.